Glucagon-like peptide-1 structure Glucagon-like peptide-1 (GLP-1) is a crucial incretin hormone with a profound impact on glucose homeostasis.作者：JJ Holst·2007·被引用次数：4330—The main actions of GLP-1 areto stimulate insulin secretion(i.e., to act as an incretin hormone) and to inhibit glucagon secretion, thereby contributing to ... Released by the intestinal lining in response to nutrient ingestion, particularly carbohydrates, GLP-1 plays a central role in regulating blood sugar levels. Its primary functions include stimulating insulin secretion and inhibiting glucagon release, thereby contributing to the control of postprandial glucose concentrations. Understanding the intricate physiology of GLP-1 is essential for comprehending its metabolic roles and therapeutic potential.
GLP-1 is derived from the proglucagon precursor, a large peptide hormone produced in specialized enteroendocrine L-cells located in the distal small intestine and colon. Through tissue-specific post-translational processing, proglucagon is cleaved to yield various peptides, including GLP-1. This peptide hormone exists in two main forms: GLP-1(7-36)amide and GLP-1(7-37)Physiology, Glucagon - StatPearls - NCBI Bookshelf. Upon its release into the circulation, GLP-1 exerts its actions through binding to specific GLP-1 receptors (GLP-1Rs) found in various tissues.
The physiological actions of GLP-1 are diverse and primarily focused on glucose metabolism. Its most significant roles include:
* Stimulation of Insulin Secretion: GLP-1 is a potent stimulator of glucose-dependent insulin secretion from pancreatic beta cells. This means that it enhances insulin release only when blood glucose levels are elevated, thereby minimizing the risk of hypoglycemia. This incretin effect is a cornerstone of its metabolic regulation.
* Inhibition of Glucagon Secretion: GLP-1 also suppresses the secretion of glucagon, a hormone produced by pancreatic alpha cells that raises blood glucose levels by promoting glycogenolysis and gluconeogenesis. By inhibiting glucagon, GLP-1 further contributes to lowering postprandial hyperglycemia2006年12月1日—GLP-1 has numerous physiological actions, including potentiation of glucose-stimulated insulin secretion, enhancement of β-cell growth and ....
* Slowing Gastric Emptying: GLP-1 acts as a physiological modulator that slows down the rate at which the stomach empties its contents into the small intestine. This effect helps to reduce the rapid absorption of nutrients, particularly glucose, leading to a more gradual rise in blood sugar after meals.
* Promoting Satiety and Reducing Food Intake: Beyond its direct effects on glucose metabolism, GLP-1 influences appetite regulation. It promotes feelings of fullness (satiety) and reduces food intake, which can contribute to weight management. These actions are conserved across species and are observed in both adolescents and adults.
* Beta-Cell Protection and Growth: Emerging evidence suggests that GLP-1 may also play a role in promoting beta-cell survival, growth, and function.Glucagon-like peptide-1 receptor: mechanisms ... - Nature This protective effect could be beneficial in conditions characterized by beta-cell dysfunction.22小时前—Incretin hormones—mainlyglucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)—enhance postprandial insulin ...
GLP-1 exerts its effects through various pathways. While primarily acting as an endocrine hormone circulating in the bloodstream to reach distant tissues, it can also act via paracrine (acting on nearby cells) and neuronal pathways to regulate physiological responses. The GLP-1 receptor is a G-protein coupled receptor (GPCR) that, upon activation by GLP-1, triggers intracellular signaling cascades that mediate the hormone's diverse effects.
In healthy individuals, GLP-1 plays a vital role in maintaining glucose balance. Disruptions in GLP-1 secretion or signaling can contribute to metabolic disorders such as type 2 diabetes and obesity. The understanding of GLP-1's physiology has led to the development of GLP-1 receptor agonists, a class of medications that mimic the actions of the native hormone. These agonists have proven effective in managing type 2 diabetes and obesity by improving glycemic control, promoting weight loss, and potentially offering cardiovascular benefitsGLP-1 physiology informs the pharmacotherapy of obesity. While semaglutide, a prominent GLP-1 receptor agonist, effectively reduces fat mass, maintaining muscle mass is crucial for overall metabolic health, and research continues to explore its impact on body composition.
The physiology of glucagon-like peptide-1 is a complex and fascinating area of endocrinology. As a key incretin hormone, GLP-1 orchestrates a range of metabolic processes, most notably regulating insulin and glucagon secretion to control blood glucose levels. Its influence extends to gastric emptying and appetite regulation, highlighting its broad impact on nutrient handling and energy balance. The continued study of GLP-1's intricate mechanisms of action not only deepens our understanding of human metabolism but also drives the development of innovative therapeutic strategies for metabolic diseases.
Join the newsletter to receive news, updates, new products and freebies in your inbox.